The Life Sciences team advised Centessa Pharmaceuticals plc (Nasdaq: CNTA) in its initial public offering of 16,500,000 American Depositary Shares, each representing one ordinary share at a public offering price of $20 per ADS, and the full exercise of the underwriters to purchase an additional 2,475,000 ADSs at the initial public offering price, less underwriting discounts and commissions. The gross proceeds to Centessa from the offering, before deducting underwriting discounts, commissions and other estimated offering expenses, totaled $379.5 million. Goodwin has advised Centessa since its inception, including its recent $250 million financing round in conjunction with the company’s acquisition of 10 biotech companies earlier this year.
Centessa is a clinical-stage company employing its innovative asset-centric business model to discover, develop, and ultimately deliver impactful medicines to patients by combining the strengths of an asset-centric model with the benefits of scale and diversification typical of larger R&D organizations.
The cross-office, international Goodwin team was led by Mitch Bloom and included partners Graham Defries, Edwin O’Connor, and associates Pablo Hernandez Romero, Kenny Walker-Durrant, and Benjamin Bechhofer. The IPO team was supported by Goodwin’s multi-disciplinary life sciences practice, lending expertise in areas such as FDA and healthcare regulatory, intellectual property, executive compensation and benefits, and tax. Such professionals included Andy Barton, Alex Apostolopoulos, Seth Gitner, Heath Ingram, Simone Otenaike, Paresh Kumar, Robert Young and Tricia Hojo.
For more details on the IPO, read the press release and articles in Endpoints, MedCity News, and Barron’s.